Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Koffiekamer Terug naar discussie overzicht

TG Therapeutics TGTX

8 Posts
| Omlaag ↓
  1. Forecast2006 6 februari 2023 10:16

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 272

      Gegeven: 405

    •    Aantal posts: 1.967

    By Sriparna Roy and Khushi Mandowara

    (Reuters) - TG Therapeutics (NASDAQ:TGTX) Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade.

    The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

    TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing.

    Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

    Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

    Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to the neurological disease.

    The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients.

    Ben benieuwd wat ie vandaag doet.

    Kind regards,

    Forecast
  6. Forecast2006 17 februari 2023 19:53

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 272

      Gegeven: 405

    •    Aantal posts: 1.967


    U.S. FDA approves TG Therapeutics' multiple sclerosis drug; shares surge
    Stock Markets Dec 28, 2022 03:20PM ET

    U.S. FDA approves TG Therapeutics' multiple sclerosis

    By Sriparna Roy and Khushi Mandowara

    (Reuters) - TG Therapeutics (NASDAQ:TGTX) Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up 47% in afternoon trade.

    The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

    TG Therapeutics said it was expecting to launch the drug, branded as Briumvi, in the first quarter of 2023, but did not give details on its pricing.

    Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

    Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

    Unlike other MS drugs that target T cells, Briumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to the neurological disease.

    The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients.
  7. Forecast2006 18 februari 2023 14:46

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 272

      Gegeven: 405

    •    Aantal posts: 1.967

    Feb 14, 2023
    NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI™ (ublituximab) in adult patients with relapsing forms of multiple sclerosis (RMS), at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual forum, being held February 23 – 25, 2023, in San Diego, California. Abstracts are now available online and can be accessed on the ACTRIMS meeting website at www.forum.actrims.org. Details of the presentations are outlined below.

    Poster Presentation Title: Early, Transient Shift in Hematologic Parameters Observed with Ublituximab in the ULTIMATE I and II Phase 3 Studies

    Presentation Date/Time: Thursday, February 23, 7:00 - 7:30 PM PST
    Session: Poster Session 1
    Abstract Number/Poster Number: 406/P071
    Lead Author: Peiqing Qian, MD, Swedish Neuroscience Institute, Seattle, WA

    CONTACT:

    Investor Relations
    Email: ir@tgtxinc.com
    Telephone: 1.877.575.TGTX (8489), Option 4

    Media Relations:
    Email: media@tgtxinc.com
    Telephone: 1.877.575.TGTX (8489), Option 6

    Kind regards,
    Forecast
  8. Forecast2006 29 februari 2024 09:17

    • Forecast2006

      Lid sinds: 30 mrt 2006

      Laatste bezoek: 25 apr 2024

    • Aanbevelingen

      Ontvangen: 272

      Gegeven: 405

    •    Aantal posts: 1.967

    Flinke stijging van de koers van 26,74 % na 4e kwartaalcijfers die beter waren dan de analisten hadden verwacht.
    Hoop dat het medicijn BRIUMVI MS patiënten gaat helpen.
    Kind regards,
    Forecast
8 Posts
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.285
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.579 46.254
ABO-Group 1 18
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.891
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.213
Aedifica 2 829
Aegon 3.257 320.033
AFC Ajax 537 7.014
Affimed NV 2 5.751
ageas 5.843 109.777
Agfa-Gevaert 13 1.856
Ahold 3.536 73.979
Air France - KLM 1.024 34.308
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.762
Alfen 12 16.182
Allfunds Group 3 1.185
Almunda Professionals (vh Novisource) 651 4.246
Alpha Pro Tech 1 17
Alphabet Inc. 1 326
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.484 114.757
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.819 240.232
AMG 965 125.630
AMS 3 73
Amsterdam Commodities 303 6.516
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.108
Apollo Alternative Assets 1 17
Apple 5 313
Arcadis 251 8.613
Arcelor Mittal 2.023 318.590
Archos 1 1
Arcona Property Fund 1 266
arGEN-X 15 9.102
Aroundtown SA 1 176
Arrowhead Research 5 9.257
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.644
ASML 1.762 76.813
ASR Nederland 18 4.122
ATAI Life Sciences 1 7
Atenor Group 1 329
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.644
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.660

Macro & Bedrijfsagenda

  1. 25 april

    1. BASF Q1-cijfers
    2. Deutsche Bank Q1-cijfers
    3. Delivery Hero Q1-cijfers
    4. Nestlé Q1-cijfers
    5. Adyen Q1-cijfers
    6. Besi Q1-cijfers
    7. Flow Traders Q1-cijfers
    8. Sanofi Q1-cijfers
    9. Azelis Q1-cijfers
    10. Kinepolis Q1-cijfers
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda